Artelo Biosciences announces 3-for-1 reverse stock split

Artelo Biosciences (ARTL) announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split of the Company’s common stock. The Company’s common shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market commencing at the market open, March 10, 2026. The Board of Directors determined the 3-for-1 ratio to be appropriate in order to increase the price per share of the Common Stock to improve its marketability and liquidity.